Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives

References

• International Diabetes FederationIDF Diabetes Atlas7th ed2015
   Google Scholar
• CDCPrevention. CfDCa. Treating diabetes (insulin and oral medication use) Available from: http://www.cdc.gov/diabetes/statistics/treating_national.htmAccessed July 18, 2016
   Google Scholar
• GreggEWChengYJSaydahSTrends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview SurveyDiabetes Care20123561252125722619288
   PubMed Web of Science ®Google Scholar
• SudharsananNAliMKMehtaNKNarayanKMPopulation aging, macroeconomic changes, and global diabetes prevalence, 1990–2008Popul Health Metr2015133326640415
   PubMed Web of Science ®Google Scholar
• PavkovMEHansonRLKnowlerWCBennettPHKrakoffJNelsonRGChanging patterns of type 2 diabetes incidence among Pima IndiansDiabetes Care20073071758176317468358
   PubMed Web of Science ®Google Scholar
• HarjutsaloVSjöbergLTuomilehtoJTime trends in the incidence of type 1 diabetes in Finnish children: a cohort studyLancet200837196261777178218502302
   PubMed Web of Science ®Google Scholar
• GillGVYudkinJSKeenHBeranDThe insulin dilemma in resource-limited countries. A way forward?Diabetologia2011541192420835860
   PubMed Web of Science ®Google Scholar
• NarayanKMBoyleJPThompsonTJGreggEWWilliamsonDFEffect of BMI on lifetime risk for diabetes in the U.SDiabetes Care20073061562156617372155
   PubMed Web of Science ®Google Scholar
• American Diabetes Association7. Approaches to glycemic treatmentDiabetes Care201639Suppl 1S52S5926696682
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• LeporeMPampanelliSFanelliCPharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lisproDiabetes200049122142214811118018
   PubMed Web of Science ®Google Scholar
• KoehlerGTreiberGWutteAPharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetesDiabetes Obes Metab2014161576223841569
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLRønnBBLower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesDiabetes20045361614162015161770
   PubMed Web of Science ®Google Scholar
• HorvathKJeitlerKBergholdALong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20072CD00561317443605
   PubMed Web of Science ®Google Scholar
• CryerPEDavisSNShamoonHHypoglycemia in diabetesDiabetes Care20032661902191212766131
   PubMed Web of Science ®Google Scholar
• DeckertTIntermediate-acting insulin preparations: NPH and lenteDiabetes Care1980356236267192205
   PubMed Web of Science ®Google Scholar
• HeinemannLLinkeschovaRRaveKHompeschBSedlakMHeiseTTime-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placeboDiabetes Care200023564464910834424
   PubMed Web of Science ®Google Scholar
• WangFCarabinoJMVergaraCMInsulin glargine: a systematic review of a long-acting insulin analogueClin Ther20032561541157712860485
   PubMed Web of Science ®Google Scholar
• DunnCJPloskerGLKeatingGMMcKeageKScottLJInsulin glargine: an updated review of its use in the management of diabetes mellitusDrugs200363161743177812904090
   PubMed Web of Science ®Google Scholar
• BeckerRHDahmenRBergmannKLehmannAJaxTHeiseTNew insulin glargine 300 units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units mL-1Diabetes Care201538463764325150159
   PubMed Web of Science ®Google Scholar
• BlairHAKeatingGMInsulin Glargine 300 U/mL: a review in diabetes mellitusDrugs201676336337426821280
   PubMed Web of Science ®Google Scholar
• RiddleMCBolliGBZiemenMNew insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)Diabetes Care201437102755276225078900
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHBergenstalRZiemenMEDITION 2 Study InvestigatorsNew insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)Diabetes Care201437123235324325193531
   PubMed Web of Science ®Google Scholar
• BolliGBRiddleMCBergenstalRMEDITION 3 study investigatorsNew insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)Diabetes Obes Metab201517438639425641260
   PubMed Web of Science ®Google Scholar
• HomePDBergenstalRMBolliGBNew insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, Phase 3a, open-label clinical trial (EDITION 4)Diabetes Care201538122217222526084341
   PubMed Web of Science ®Google Scholar
• MatsuhisaMKoyamaMChengXEDITION JP 1 study groupNew insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)Diabetes Obes Metab201618437538326662964
   PubMed Web of Science ®Google Scholar
• TerauchiYKoyamaMChengXNew insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)Diabetes Obes Metab201618436637426662838
   PubMed Web of Science ®Google Scholar
• JinnouchiHKoyamaMAmanoAContinuous glucose monitoring during basal-bolus therapy using insulin glargine 300 U mL(−1) and glargine 100 U mL (−1) in Japanese people with type 1 diabetes mellitus: a crossover pilot studyDiabetes Ther20156214315226055218
   PubMed Web of Science ®Google Scholar
• RiddleMCYki-JärvinenHBolliGBOne-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extensionDiabetes Obes Metab201517983584225846721
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHBergenstalRMBolliGBGlycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus insulin glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensionDiabetes Obes Metab201517121142114926172084
   PubMed Web of Science ®Google Scholar
• RitzelRRousselRBolliGBPatient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetesDiabetes Obes Metab201517985986725929311
   PubMed Web of Science ®Google Scholar
• LiTPuhanMAVedulaSSSinghSDickersinKAd Hoc Network Meta-analysis Methods Meeting Working GroupNetwork meta-analysis-highly attractive but more methodological research is neededBMC Med201197921707969
   PubMed Web of Science ®Google Scholar
• FreemantleNChouEFroisCSafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisBMJ Open201662e009421
   Web of Science ®Google Scholar
• Martyn-NemethPSchwarz FarabiSMihailescuDNemethJQuinnLFear of hypoglycemia in adults with type 1 diabetes: impact of herapeutic advances and strategies for prevention – a reviewJ Diabetes Complications201630116717726439754
   PubMed Web of Science ®Google Scholar
• BrodMWoldenMChristensenTBushnellDMA nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily functionDiabetes Obes Metab201315654655723350726
   PubMed Web of Science ®Google Scholar
• BrodMChristensenTBushnellDMImpact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country surveyJ Med Econ2012151778622029460
   PubMedGoogle Scholar
• BrodMWoldenMChristensenTBushnellDMUnderstanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilizationValue Health20131681140114924326167
   PubMed Web of Science ®Google Scholar
• SeaquistERAndersonJChildsBHypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine societyDiabetes Care20133651384139523589542
   PubMed Web of Science ®Google Scholar
• International Hypoglycaemia Study GroupMinimizing hypoglycemia in diabetesDiabetes Care20153881583159126207052
   PubMed Web of Science ®Google Scholar
• HellerSRCryerPEReduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humansDiabetes19914022232261991573
   PubMed Web of Science ®Google Scholar
• BoylePJKempersSFO’ConnorAMNagyRJBrain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitusN Engl J Med199533326172617317491135
   PubMed Web of Science ®Google Scholar
• AmielSASherwinRSSimonsonDCTamborlaneWVEffect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone releaseDiabetes19883779019073290007
   PubMed Web of Science ®Google Scholar
• BoylePJSchwartzNSShahSDClutterWECryerPEPlasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabeticsN Engl J Med198831823148714923285214
   PubMed Web of Science ®Google Scholar
• JonesTWPorterPSherwinRSDecreased epinephrine responses to hypoglycemia during sleepN Engl J Med199833823165716629614256
   PubMed Web of Science ®Google Scholar
• GaisSBornJPetersAHypoglycemia counterregulation during sleepSleep2003261555912627733
   PubMed Web of Science ®Google Scholar
• SchwartzNSClutterWEShahSDCryerPEGlycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptomsJ Clin Invest19877937777813546378
   PubMed Web of Science ®Google Scholar
• MitrakouARyanCVenemanTHierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunctionAm J Physiol19912601 Pt 1E67E741987794
   PubMed Web of Science ®Google Scholar
• FreckmannGBaumstarkAJendrikeNSystem accuracy evaluation of 27 blood glucose monitoring systems according to DIN EN ISO 15197Diabetes Technol Ther201012322123120151773
   PubMed Web of Science ®Google Scholar
• KingABClarkDWolfeGSContribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargineEndocr Pract201218455856222548951
   PubMed Web of Science ®Google Scholar
• RiddleMCBolliGBHomePDEfficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetesDiabetes Technol Ther201618425225726840338
   PubMed Web of Science ®Google Scholar
• BeckerRHNowotnyITeichertLBergmannKKapitzaCLow within- and between-day variability in exposure to new insulin glargine 300 U/mLDiabetes Obes Metab201517326126725425394
   PubMed Web of Science ®Google Scholar
• VoraJCariouBEvansMClinical use of insulin degludecDiabetes Res Clin Pract20151091193125963320
   PubMed Web of Science ®Google Scholar
• CaparrottaTMEvansMPEGylated insulin Lispro, (LY2605541) – a new basal insulin analogueDiabetes Obes Metab201416538839523941279
   PubMed Web of Science ®Google Scholar
• Russell-JonesDGallMANiemeyerMDiamantMDel PratoSInsulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trialsNutr Metab Cardiovasc Dis2015251089890526232910
   PubMed Web of Science ®Google Scholar
• LaneWBaileyTSGeretyGSWITCH 1: reduced risk of hypoglycaemia with insulin degludec vs insulin glargine U100 in patients with type 1 diabetes: a randomised, double-blind, crossover trialDiabetologia201659Suppl 1S42S43
   Google Scholar
• CarrisNWTaylorJRGumsJGCombining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerationsDrugs201474182141215225414121
   PubMed Web of Science ®Google Scholar
• VedtofteLKnopFKVilsbøllTFixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutideExpert Rev Clin Pharmacol20158327328225816888
   PubMed Web of Science ®Google Scholar